- Question from Tonio: Hello from Spain. My wife, 37 years old, was diagnosed with invasive ductal carcinoma (T1N0M0), 2 cm., ER+, PR+, c-erbB-2- (HER-2/neu negative). She has been treated with 6 x CMF, finishing last week, but we believe that it is not the optimum treatment. Would it be possible to add any anthracycline or taxane regimen now?
Jennifer Griggs, M.D., M.P.H.
Actually, the treatment you've outlined is excellent. Although very large studies suggest a possible benefit to regimens that contain an anthracycline, there are no features of your wife's tumor that make me think this class of drug would be necessary. I am assuming that she will also go on a hormonal-acting agent, such as tamoxifen.
Tumors that have the c-erbB-2- (in other words, are negative for HER-2/neu) can get a good response to CMF chemotherapy as well as to Adriamycin chemotherapy, but tumors that are HER-2 positive may respond better to an Adriamycin-based or a taxane-based chemotherapy.
On Wednesday, February 18, 2004, our Ask-the-Expert Online Conference was called Chemotherapy Updates. Jennifer Griggs, M.D., M.P.H. and Marisa Weiss, M.D. answered your questions about advances in chemotherapy treatment: different types of drugs and regimens, how to reduce or eliminate unpleasant side effects, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.